Related Experiment Video
Updated: May 24, 2026
08:40
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
Chromogranin A--serum marker for prostate cancer
Muhammad Owais Khan1, Mohammad Hammad Ather
1Dow Medical College, Karachi.
JPMA. the Journal of the Pakistan Medical Association
|February 29, 2012
Summary
Chromogranin A (CgA) can help predict prostate cancer prognosis, especially in cases with low Prostate Specific Antigen (PSA). Elevated CgA indicates neuroendocrine differentiation and may signal resistance to endocrine therapy.
Area of Science:
- Oncology
- Biochemistry
- Urology
Background:
- Prostate cancer is a leading male neoplasm, often linked to family history.
- Prostate Specific Antigen (PSA) is a key diagnostic and monitoring biomarker.
- Chromogranin A (CgA) is a glycoprotein elevated in neuroendocrine differentiation.
Purpose of the Study:
- To evaluate Chromogranin A (CgA) as a predictive marker in prostate cancer.
- To assess the combined utility of CgA and PSA for prognosis.
- To investigate CgA's role in predicting resistance to endocrine therapy.
Main Methods:
- Measurement of serum Prostate Specific Antigen (PSA) and Chromogranin A (CgA).
- Analysis of CgA expression in prostate cancer biopsies.
- Correlation of CgA levels with tumor grade, PSA levels, and response to therapy.
Main Results:
- Elevated CgA is associated with neuroendocrine differentiation in prostate cancer.
- High CgA and low PSA may indicate poor prognosis and resistance to endocrine therapy.
- CgA expression in biopsies independently predicts hormone-refractory disease.
Conclusions:
- Serum CgA is a valuable biomarker, particularly when PSA levels are low.
- Combined CgA and PSA assessment improves prognostic prediction after endocrine therapy.
- CgA aids in identifying patients likely to develop hormone-refractory prostate cancer.
